Stockscreener 앱 받기
0.5439
2.91%
0.0154
시간 외 거래:
.54
-0.0039
-0.72%
전일 마감가:
$0.5285
열려 있는:
$0.5327
하루 거래량:
547.00K
Relative Volume:
1.09
시가총액:
$39.39M
수익:
-
순이익/손실:
$-101.87M
주가수익비율:
-0.473
EPS:
-1.15
순현금흐름:
$-83.46M
1주 성능:
-4.68%
1개월 성능:
-14.53%
6개월 성능:
-39.77%
1년 성능:
-52.70%
1일 변동 폭
$0.5314
$0.5491
1주일 범위:
$0.5202
$0.58
52주 변동 폭
$0.5202
$1.20
Kezar Life Sciences Inc Stock (KZR) Company Profile
명칭
Kezar Life Sciences Inc
전화
650-822-5600
주소
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-03-16 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Wells Fargo | Outperform |
| 2018-07-16 | 개시 | William Blair | Outperform |
Kezar Life Sciences Inc 주식(KZR)의 최신 뉴스
Quarterly Snapshot: Quick and Current Ratios for Kezar Life Sciences Inc (KZR) - The Dwinnex
Check out these key findings about Kezar Life Sciences Inc (KZR) - SETE News
KZR’s Stock Journey: What Investors Need to Know About Kezar Life Sciences Inc’s Performance - The InvestChronicle
Selling Buzz: Kezar Life Sciences Inc [KZR] Chief Legal Officer Schiller Mark C. sells 6,688 shares of the company - Knox Daily
Kezar Life Sciences stock hits 52-week low at $0.53 By Investing.com - Investing.com Australia
A look at KZR’s current quarter earnings estimates - US Post News
Kezar Life Sciences stock hits 52-week low at $0.53 - Investing.com
Acadian Asset Management LLC Raises Stake in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Perhaps timely catching Kezar Life Sciences Inc (KZR) would be a good idea - SETE News
Kezar Life Sciences Inc’s Shares Reel: -3.60% Quarterly Revenue Decline Amid 49.58M Market Cap - The InvestChronicle
Kezar Life Sciences, Inc. (NASDAQ:KZR) Sees Significant Decrease in Short Interest - Defense World
Kezar Life Sciences, Inc. (NASDAQ:KZR) Shares Bought by Vanguard Group Inc. - Defense World
Kezar Life Sciences (STU:2KZ) Enterprise Value : €-92.80 Mil (As of Aug. 17, 2024) - GuruFocus.com
Brokers Offer Predictions for Kezar Life Sciences, Inc.’s FY2024 Earnings (NASDAQ:KZR) - Defense World
Kezar Life Sciences, Inc. (NASDAQ:KZR) to Post Q3 2024 Earnings of ($0.30) Per Share, William Blair Forecasts - Defense World
What is the investor’s view on Kezar Life Sciences Inc (KZR)? - US Post News
HC Wainwright Reiterates Buy Rating for Kezar Life Sciences (NASDAQ:KZR) - Defense World
KZR’s 52-Week Rollercoaster: From $0.54 to $1.68 – What’s Next for Investors? - The InvestChronicle
Kezar Life Sciences Maintains Buy Rating, Focus Shifts to Zeto Trials - Investing.com Canada
Kezar Life Sciences Maintains Buy Rating, Focus Shifts to Zeto Trials - Investing.com UK
Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug - Benzinga
Kezar stalls solid tumour trial to focus on autoimmune disease candidate - Yahoo Finance
Kezar stalls solid tumour trial to focus on autoimmune disease candidate - Clinical Trials Arena
Kezar stalls solid tumour trial to focus on autoimmune disease candidate - Pharmaceutical Technology
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024 - InvestorPlace
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Manchestertimes
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Business Wire
Head to Head Survey: Neurogene (NASDAQ:NGNE) & Kezar Life Sciences (NASDAQ:KZR) - Defense World
Polymyositis Drugs Market Size 2032 | Argenx, Immunoforge Co. - openPR
Jacobs Levy Equity Management Inc. Cuts Stock Position in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
Kezar Life Sciences' chief legal officer sells shares worth $3,879 - Investing.com
How did Kezar Life Sciences Inc (KZR) fare last session? - US Post News
Kezar Life Sciences, Inc. (NASDAQ:KZR) Shares Purchased by BNP Paribas Financial Markets - Defense World
Polymyositis Market to Show Remarkable Growth Trends from 2023 - openPR
Acadian Asset Management LLC Increases Stock Position in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
Kezar Life Sciences (NASDAQ:KZR) Given New $7.00 Price Target at HC Wainwright - Defense World
Kezar Life Sciences Inc (KZR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
You might want to take a look at Kezar Life Sciences Inc (KZR) now - SETE News
Kezar Life Sciences (NASDAQ:KZR) Trading 2.4% Higher - Defense World
Kezar Life Sciences Inc (KZR) presents a great opportunity, but the stock is slightly undervalued - US Post News
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Metric Deep Dive: Understanding Kezar Life Sciences Inc (KZR) Through its Ratios – DWinneX - The Dwinnex
Kezar Life Sciences Inc [KZR] Is Currently 0.02 below its 200 Period Moving Avg: What Does This Mean? – The DBT ... - The DBT News
There is no way Kezar Life Sciences Inc (KZR) can keep these numbers up - SETE News
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - WICZ
Kezar Life Sciences Inc (KZR) is a good investment, but the stock may be undervalued – US Post News - US Post News
Ratio Revelations: Kezar Life Sciences Inc (KZR)'s Financial Metrics in the Spotlight – DWinneX - The Dwinnex
Why Kezar Life Sciences Stock Is Crushing It Today - The Globe and Mail
Analyst Expectations for Kezar Life Sciences's Future - Quantisnow
Kezar Life Sciences Inc (KZR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
자본화:
|
볼륨(24시간):